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The central question of human cancer immunology continues to be whether 
malignant transformation is associated with antigenic changes that can be rec- 
ognized as foreign by the host of origin. Our laboratory has been addressing this 
question  through the analysis of the humoral immune reactions of patients to 
surface antigens of cancer cells. The approach we have evolved in these studies 
has been  referred to as autologous typing and consists of identifying patients 
with  antibodies  to  surface  antigens  of cultured  autoiogous  tumor  cells  and 
analyzing the specificity of these reactions by absorption  tests with autologous 
and  allogeneic  normal  and  malignant  cells  (1).  Three  classes  of cell  surface 
antigens  have  been  defined  in  this  way  through  the  study  of patients  with 
melanoma (2-6),  astrocytoma (7), renal cancer (8), and acute leukemia (9,  10). 
Class 1 tumor antigens show an absolute restriction to the autologous tumor and 
cannot be detected on any other normal or malignant cell type. Class 2  tumor 
antigens are also found on a  proportion of allogeneic tumors of related origin 
and, in certain instances, on a  limited range of normal cell types. As shown by 
Watanabe et al. (1 1), some of these antigens have the characteristics of autoan- 
tigenic differentiation antigens. Class 3 tumor antigens have a broad distribution 
on normal and malignant cell types and do not follow any differentiation-related 
or tumor-restricted pattern. 
In our study of 85 patients with malignant melanoma, autologous typing has 
identified 5 patients with antibodies to Class 1 tumor antigens (1-3,  5, 6). Four 
of these antibodies belonged to the IgG class and the fifth was an IgM antibody. 
Partial characterization of one of the Class 1 melanoma antigens (AU) was carried 
out  using  papain-solubilized  antigen  in  conjunction  with  antibody  inhibition 
assays (12).  AU antigen appeared to be a  glycoprotein (as indicated by affinity 
for lentil lectin), showed no relation to HLA or/32 microglobulin (/32m),'and had 
a  molecular  mass  in  the  range  of 25,000-40,000  daltons.  Despite  repeated 
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attempts none of the  antibodies  to Class  1 melanoma antigens  immunoprecipi- 
tated antigen from radiolabeled cell extracts. 
In  this  report,  we  describe  a  new  Class  1  melanoma  antigen  detected  by 
antibody in the sera of patient  FD.  FD sera reacted exclusively with autologous 
FD melanoma cells and immunoprecipitated a  90,000 dalton glycoprotein from 
extracts of radiolabeled FD melanoma cells. 
Materials and  Methods 
Tissue Culture.  Tumor cell  lines were established and propagated as previously de- 
scribed  (2,  7,  8).  B  cell  lines  were  established  from peripheral  blood  lymphocytes of 
melanoma patients transformed by Epstein-Barr virus (EBV) released from the  B-95-8 
marmoset lymphoid cell line. Cultured cells were maintained in Eagle's minimum essential 
medium supplemented with  2  mM glutamine,  1%  nonessential amino acids,  100  U/ml 
penicillin,  100  #g]ml streptomycin, and  7.5%  fetal bovine serum (FBS)  (complete me- 
dium).  To  remove heterologous  FBS  components,  SK-MEL-131  (FD)  melanoma cells 
were grown for at least four subcultures in 10% human sera selected from AB blood type 
donors. SK-MEL-131 cells were also adapted to growth in serum-free medium containing 
insulin (5 •g/ml),  transferrin (5 ~g]ml), and selenium (5 ng]ml) (ITS medium; Collabo- 
rative  Research,  Inc.,  Waltham,  MA).  A  series  of subcultures  of SK-MEL-131  were 
obtained by fimiting dilution  in  wells  of Costar 3596  plates (Costar, Cambridge,  MA). 
Cells were seeded at a concentration of 100, 10, or 1 cell per well. Cultures were checked 
for the presence of a  single growing cluster of cells,  and wells  containing such clusters 
were subcultured  and  expanded.  Cultures  were regularly tested  for mycoplasma, and 
contaminated cultures were discarded. 
Serological  Tests.  The  protein  A  (PA)  hemadsorption  and  immune adherence  (IA) 
assays were performed as previously described (2-4,  7).  Indicator cells for the human 
mixed hemadsorption (MHA) assay were prepared using a human serum that contained 
natural  hemagglutinating  antibodies  reactive  with  sheep  erythrocytes,  and  goat  anti- 
human Ig (Cappel Laboratories, Cochranville, PA) as the second antibody. Assays were 
performed in Falcon 3040 microtest I1 plates (Falcon Labware, Oxnard, CA). Target cells 
were  plated  1-3  d  before  the  assay  and  incubated  with  antibody  for  1  h  at  room 
temperature. After washing with 5% gamma globulin-free FBS (GGF-FBS) (Gibco Lab- 
oratories,  Grand  Island,  NY)  in  phosphate-buffered  saline  (PBS),  indicator  cells were 
added and incubated with the target cells for 1 h at room temperature. The plates were 
then washed three times with 5% GGF-FBS-PBS and reactions were evaluated under a 
light microscope. Titer refers to the highest serum dilution showing 10% of target cells 
with red cells attached to 50% or more of their perimeter. In tests with cells grown in 
human serum, 2% human serum albumin in PBS was substituted for the 5% GGF-FBS- 
PBS.  Qualitative absorptions were performed by mixing 30 ~i  of a  dilution  of serum 
(fourfold more concentrated  than  the serum dilution  giving 50%  rosetted target cells) 
with a 30 #1 pellet of packed cells for 30 min at room temperature and 30 rain at 4°C. 
For quantitative absorptions, the cell pellet (ranging from 1 to 30 ~1) was suspended in 30 
~1 of similarly diluted serum and incubated for 30 min at room temperature and 30 min 
at 4°C. 
To detect shed antigens in spent culture medium, medium from SK-MEL-131 cells (or 
from normal human fibroblasts) was collected, ultracentrifuged at 100,000 g for 30 min, 
and tested for antibody inhibitory activity by serially diluting FD serum in the medium. 
After a 30 rain incubation at room temperature, residual antibody activity was determined 
using SK-MEL-131 target cells. To test for the heat stability of FD antigen, SK-MEL-131 
cells  were  incubated  for  5  rain  in  boiling  water  and  then  tested  for  FD  antigen  in 
absorption tests. Sensitivity to neuraminidase was determined by incubating attached SK- 
MEL-I 31 cells in Dulbecco's PBS (Gibco Laboratories) containing neuraminidase (Calbi- 
ochem-Behring Corp., La Jolla, CA) at a concentration of 50 U/ml for 1 h at 37 °C before 
the serological assay. Trypsin sensitivity was determined by incubating SK-MEL-131 cells 
with trypsin (Gibco Laboratories) at a concentration of 0.5  mg/ml for 10 min at 37°C. REAL  ET AL.  1221 
To investigate the  reappearance of FD antibody, trypsinized SK-MEL-131  cells were 
washed and incubated for 0.5 and 6 h in complete medium containing (a) no additive, (b) 
cycloheximide (Sigma Chemical Co., St. Louis, MO) at a concentration of 10 ~g/ml or (c) 
monensin (Sigma Chemical Co.) at a concentration of 10 ~g/mi. The IgG fraction of FD 
serum was  obtained by DEAE-Sepharose chromatography (Pharmacia  Fine Chemicals, 
Piscataway, N  J). 
Immunoprecipitation.  Metabolic incorporation of [SH]glucosamine (13), [SH]mannose 
(13), or [sSS]methionine (14) and solubilization of labeled cells (15) have been previously 
described.  Membrane  preparations  were  solubilized with  Nonidet  P-40  (Calbiochem- 
Behring Corp.) and ~gI-labeled with chloramine T  (Eastman Kodak Co., Rochester, NY) 
(16). Culture medium from SK-MEL-131 cells grown in ITS medium was concentrated 
10 times by pressure dialysis using an Amicon membrane (Amicon Corp., Danvers, MA) 
with a  10,000 dalton exclusion limit and then dialyzed for 72 h against PBS. Iodination 
was performed as described (16), except that the column buffer was 50 mM Tris, pH 7.5, 
2% BSA,  10 mM  NaI, 0.10 M  NaCI (buffer A).  Immunoprecipitation techniques have 
also been previously described (16). Immunoprecipitated molecules were extracted from 
pelleted Staphylococcus aureus (Enzyme Center, Boston, MA) with 60 #1 0.01 M Tris HCI, 
pH 7.2, 2% sodium dodecyl sulfate (SDS),  12 mg/ml dithiothreitol (DTT), 15% (wt/vol) 
sucrose, and 0.01% (wt/vol) pyronin Y by heating for 5 rain at 100°C, and were analyzed 
by polyacrylamide gel electrophoresis (PAGE) (17) using 9% gels.  For two-dimensional 
electrophoresis (isoelectric focusing followed by SDS-PAGE), immune precipitates were 
extracted and processed as described (13, 18). For unreduced samples, DTT was omitted 
and 14 mg/ml iodoacetamide was added to the sample. To analyze the specificity of the 
immunoprecipitating antibody in FD serum, absorption tests were performed. 30 #1 of a 
1:2 dilution of FD serum was absorbed with a 30 ttl cell pellet of autologous or ailogeneic 
cells for 30 min at room temperature and then for 30 rain at 4°C. After removing the 
absorbing cells, FD serum was tested for residual immunoprecipitating activity. 
Lectin  Column Fractionation.  Beads conjugated with concanavalin A  (Con A), wheat 
germ agglutinin,  Lentil lectin or Helix pomatia  lectin were purchased from Pharmacia 
Fine Chemicals and beads conjugated with peanut agglutinin, soybean agglutinin, and 
lectins from  Ulex  europaeus-I,  Bandeira  simplicifolia-I,  Dolichos  biflorus,  Pisum  sativum, 
Ricinus communis-I,  Vicia viUosa, Lotus tetragonolobus,  and Limulus potyphemus  were pur- 
chased from E-Y Laboratories, San Mateo, CA. Columns (0.5 ml) were equilibrated with 
buffer A  (see  above) and  ~I-labeled  antigen  preparations  were  passed  through  the 
column. Material specifically bound to the column was eluted with the appropriate sugar 
at a  1 M concentration. 
Results 
Clinical History of Patient FD.  Patient FD was a  white male who presented in 
1964 at age 50 with a primary melanoma of the right ear. He had a local excision 
and remained healthy until  1977 when a second primary melanoma was excised 
from  his  left  upper  back.  Pathological  examination  of the  lesion  revealed  a 
Clark's  level III melanoma  of 2  mm thickness.  Due to regional recurrence, he 
underwent a  left axillary dissection in  August  1979, and  4  of 23  lymph nodes 
were  found  to  contain  metastatic  melanoma.  The  SK-MEL-131  cell  line  was 
established from a left axillary metastasis excised in February 1980. A right lung 
metastasis was detected in April  1980 and the patient received leukocyte buffy- 
coat interferon. Because of disease progression, he was treated with four cycles 
of dacarbazine and achieved a  partial  response.  He also received four subcuta- 
neous injections of vesicular stomatitis virus (VSV) lysate of SK-MEL-131  cells 
during  February  and  March,  1981.  He  was  then  treated  with  cis-platinum, 
vindesine, carmustine, and tamoxifen. His disease continued to progress and the 
patient  died  at  another  institution  in  November  1981.  At  autopsy,  widely 1222  CLASS  1  (UNIQUE)  GLYCOPROTE1N  OF  HUMAN  MELANOMA 
metastatic melanoma was found.  Patient FD also had a clinical  history of men- 
ingioma and Paget's disease of bone. 
Reactivity  of FD  Serum  with  Cultured  Autologous Melanoma  Cells  (SK-MEL- 
131).  Sera from patient FD were tested for reactivity with cell surface antigens 
of the  autologous SK-MEL-131  cell  line.  Autologous reactions  were  detected 
with  PA and  human  MHA  assays,  but not  with  the  IA assay  (Fig.  1).  DEAE- 
Sepharose chromatography of FD sera showed that the reactivity was present in 
the  IgG  fraction.  SK-MEL-131  cells  cultured  for  four  or  more  passages  in 
medium  containing  normal  human  serum  (rather  than  FBS)  continued  to  be 
reactive  with  FD serum,  indicating  that  heterologous serum components were 
not involved in the reactions observed. Fig. 2 summarizes the results of tests with 
15 individual serum specimens obtained from patient  FD over a  15-mo period. 
Serum specimens obtained between February and April,  1980 were not reactive. 
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FIGURE  l.  Reactivity  of  serum  from  patient  FD  with  autologous  SK-MEL-13I  cells  as 
determined  by three  serological  assays:  (O)  immune adherence;  (@)  protein  A; (A) mixed 
hemadsorption. 
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FIGURE 2.  Reactivity of sequential serum samples from patient FD with autologous SK-MEL- 
131  melanoma cells. Serological test:  protein A assay. REAL ET  AL.  1223 
Reactivity was found with serum obtained in June 1980 (titer 1:128), and serum 
titers ranged from 1:128  to 1:512 over the next 8  mo. After four vaccinations 
with  a  VSV-lysate  of SK-MEL-131  cells  during  February and  March,  1981, 
serum  titers  rose  to  1:2048.  No  serum  specimens  were  obtained after  April 
1981. 
Absorption Analysis  of FD Serum Reactivity.  The specificity of FD autologous 
reactivity was  analyzed by  absorption  tests.  An  individual absorption  test  is 
illustrated in Fig. 3 and the results of the complete analysis are summarized in 
Table I. Of the 34 melanoma cell lines tested, only SK-MEL-131 cells absorbed 
autologous reactivity. SK-MEL-131 cells adapted to growth in human serum or 
in serum-free medium absorbed autologous reactivity completely, further dem- 
onstrating that heterologous serum components contributed by FBS were not 
involved in  FD  serum  reactivity.  A  variety of other  cell  types were  used  in 
absorption tests;  these included 32  cell  lines derived from other tumor types, 
EBV-transformed lymphocytes of eight individuals including patient FD,  and 
normal kidney epithelial cells and normal skin fibroblasts.  None of these cells 
had absorbing activity. These absorption  tests indicate that  FD  sera  detect a 
Class  1 or unique antigen on FD (SK-MEL-131) melanoma cells and that the FD 
antigen is distinct from the five other Class  1 antigens previously defined on 
melanoma cells: AU (SK-MEL-28), BD (SK-MEL-13), BI (MeWo), DX (SK-MEL- 
93), and FT (SK-MEL-147). 
Allogeneic Typing with Serum from Patient FD.  A serum specimen obtained in 
February  1981  with a  titer  of 1:1280  for autologous SK-MEL-131  cells  was 
tested on a panel of 63 allogeneic cell lines and one culture of normal allogeneic 
melanocytes (Table II). No reactivity was detected with any of these allogeneic 
cells.  To determine whether  FD reactivity could be  transferred to allogeneic 
melanoma cells,  three  melanoma cell  lines (SK-MEL-26, -43,  and  -127)  were 
incubated  for  5  d  with  supernatants  from  SK-MEL-131  cultures  and  then 
cultured  in  fresh  medium  for  3  wk.  No  FD  reactivity was  induced in  these 
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FIGURE  3.  Absorption analysis of the protein A  reactivity of FD serum (March  1981)  for 
autologous SK-MEL-131  melanoma cells.  SK-MEL-131  cells absorbed  FD serum  reactivity 
completely. SK-MEL-28, SK-MEL-37, SK-MEL-93 allogeneic  melanoma  cells and EBV-trans- 
formed  B  cells  from  patient FD did not absorb FD serum reactivity.  (Q) Unabsorbed. Absorbed 
with (O) SK-MEL-131; (A) SK-MEL-28; (1"1) SK-MEL-37; (&)SK-MEL-9B; (11) FD EBV-trans- 
formed B cells. Serological  test: protein A assay. 1224  CLASS  1 (UNIQUE)  GLYCOPROTEIN  OF  HUMAN  MELANOMA 
TABLE  I 
Absorption Analysis of FD Serum Reactivity  for Autologous SK-MEL-131 Melanoma Cells: 
Summary of Results 
Positive absorption  Negative absorption 
Melanomas  Melanomas  Renal carcinomas 
SK-MEL-131 (FBS) 
SK-MEL-131 (NHS) 
SK-MEL-131 (ITS) 
SK-MEL-13, 19, 23(I), 26, 28, 29, 33, 
37, 40, 42, 44, 57, 61, 67, 72, 75, 
90, 93(I), 93(II), 93(III), 94, 110, 
111, 119, 122, 147, 158, 161, 162, 
165, 169, MeWo, WM77 
Astrocytomas 
SK-MG-3, 5, 6, 9, 12, U251 MG, MS 
Bladder carcinomas 
Scaber, RT4, T24,486-P, 639-V, 
647-V, 253-J 
Lung carcinomas 
SK-LC-6, 8, Calu-1 
SK-RC-1, 2, 4, 6, 7, 9, 11, 16, 
18, 28 
Other carcinomas 
MCF-7 (breast), ME- 180 
(cervix), HT-29 (colon), 
SW-620 (colon), GCC-SV(C) 
(choriocarcinoma) 
B lymphocyte lines 
(EBV-transformed) 
WM51, FD(a,utologous),  AZ, 
AV, BD, FG, DX, El 
Normal cells 
Skin fibroblasts (DX, EZ) 
Fetal fibroblasts (Flow 5000) 
Kidney epithelium (KM, KU, 
KY,NO) 
Type 0  erythrocytes 
Xenogeneic cells 
Sheep erythrocytes 
VERO (monkey kidney) 
CHO (hamster ovary) 
B16 (mouse melanoma) 
allogeneic melanomas, suggesting that a transmissible agent, such as a virus, was 
not involved in FD antigen expression. 
Characteristics of FD Antigen.  Absorption tests with SK-MEL-131 cells heated 
for 5  min at  100°C  showed  that  FD  antigen  was  heat  labile.  Treatment  with 
trypsin also destroyed FD antigen expression.  No antigen could be detected at 
0.5 h  after trypsinization, but FD expression was partially restored at  12 h  and 
reached  maximal  levels at  48-72  h  after  trypsinization.  Reexpression  of FD 
antigen  was  inhibited  completely by cycloheximide and  partially by monensin 
(Fig. 4). Neuraminidase treatment of adherent cells did not affect the expression 
of FD antigen but abolished the reactivity of R24 antibody, which reacts with GD3 
disialoganglioside (Fig.  5).  Absorption tests indicated that FD antigen could be 
detected in conditioned medium from SK-MEL-131 cells and that centrifugation 
at  100,000 g for 2 h  did not sediment the antigen. 
A  progressive  decline  in  the  expression  of  FD  antigen  was  found  during 
successive passaging of SK-MEL-131 cells (Fig. 6). The titer of FD serum (March 
1981) tested on SK-MEL-131  cells at passage  7  (10  wk after culture initiated) 
was  1:1280. Eight weeks later, at passage  14, the titer was  1:320. After 8  wk of 
further culture, the titer decreased to 1:80, and after 10 mo of culture the titer 
was < 1  : 10. This decline in antigen expression was related to time in culture and 
not  to  passage  number;  this  was  established  by  testing  cells  that  had  been REAL  ET  AL.  1225 
TABLE  II 
allogeneic Typing with FD Serum: Lack of Reactivity of FD Serum with Cell Surface Antigens 
of 63 Cultured  Cell Types 
Negative cell lines 
Melanomas 
SK-MEL-I 3, 19, 21, 23(I), 26, 27, 28, 33, 37, 41, 
75, 93(I),  113,  119,  127,  143,  147, 
153,  158,  161 
Astrocytomas 
U251  MG, AN, AS 
Neuroblastomas 
SK-N-MC, SH-EP, LA-N-Is 
Renal carcinomas 
SK-RC-6, 7, 9, 29, 31, 37, 39, 42, 44 
Colon carcinomas 
HT29, SW48, SW676, SW1083, SW1417, 
SK-CO-1,  10, 11 
Bladder carcinomas 
T24, 253-J, Scaber 
Teratocarcinomas 
Tera- 1, Tera-2 
Lung carcinomas 
SK-LC-6,13 
Ovarian carcinomas 
SK-OV-3, 2774 
Pancreatic carcinomas 
ASPC-  1, Capan- 1 
Other carcinomas 
MCF-7 (breast); GCC-SV(C)  (cho- 
riocarcinoma);  SK-UT-1  (uter- 
ine) 
B Lymphocyte lines 
(EBV-transformed) 
FD, AU, AV 
Normal cells 
Kidney epithelium 
Fetal brain cells 
Fetal fibroblasts 
Melanocytes 
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FmURE 4.  Reactivity of FD serum with SK-MEL-131 cells after trypsin treatment. Reexpres- 
sion  of FD  antigen  is  completely inhibited by  cycloheximide and  partially inhibited by 
monensin. ((3, A, I-1) Protein A assay performed 0.5 h after trypsinization; (0, A, II) protein A 
assay performed 6 h after trypsinization. (A, A) untreated; (1"3, II) monensin treatment; (O, O) 
cycloheximide treatment. Serological test: protein A assay. 
subcuhured 14 vs. 4  times over a period of 6  mo. Reactivity with eight mouse 
monoclonal antibodies to unrelated cell surface antigens of SK-MEL-131 did not 
vary significantly during prolonged culture. Absorption tests indicated that FD 
antigen continued to  be expressed in  SK-MEL-131  cells even after a  year in 1226  CLASS  l  (UNIQUE)  GLYCOPROTEIN  OF  HUMAN MELANOMA 
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FXC,  URE  5.  Reactivity of FD serum with SK-MEL-131 melanoma cells after neuraminidase 
treatment. Neuramindase does not affect FD antigen expression, but abolishes reactivity with 
R2~ monoclonal antibody-detecting GD~ disialoganglioside.  (0, I) Untreated; (O, n) neuramin- 
idase treatment. (O, 0) FD serum; (1"-1,  I) R~4 monoclonal antibody. Serological  test: protein A 
assay. 
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FIGURE 6.  Reactivity of FD serum (March 1981) of patient FD with autologous SK-MEL- 
131 melanoma cells kept in continuous culture for 12 mo. Serological test: protein A assay. 
continuous passage,  despite  the  fact that  no  FD  antigen  could be detected in 
direct tests. SK-MEL-131 cells stored at -70°C  after varying periods of culture 
retained their characteristic prestorage reactivity with FD sera. 
Subcultures  obtained  by  limiting  dilution  of early passages  of SK-MEL-131 
yielded  lines  with  stable  high  or  low  antigen  expression  (Fig.  7).  One  line 
designated  1.36 has been cultured for 26 mo and maintains reactivity with FD 
serum  at  a  titer  of  1:320.  12  sublines  of  1.36  have  been  isolated  by  limiting 
dilution, and the majority of these maintain high FD antigen expression (Fig. 7), 
although  there is a  variation in the amount of antigen expressed by individual 
sublines as indicated by direct tests and quantitative absorption analysis (Fig. 8). 
A  variety  of agents  were  tested  for  their  ability  to  influence  FD  antigen 
expression. SK-MEL-131 cells were incubated for 48 h in the presence of cholera 
toxin, dibutyryl cAMP,  theophylline, phorbol-12-myristate-13-acetate,  5-azacy- 
tidine,  retinoic  acid,  nerve  growth  factor,  a-interferon,  /3-interferon,  y-inter- 
feron, phytohemagglutinin, or Con A. No change was found in the reactivity of REAL  ET  AL.  1227 
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FIGURE 7.  Reactivity of FD serum with subcultures of SK-MEL-131  melanoma cells. Lines 
2.42 (O), 3.44 (D), 3.45 (A), and  1.36  were derived by limiting dilution from parental SK- 
MEL-131  after 2 mo in culture (passage 9). Sublines  1.36-1-5 (O), 1.36-1-9 (am), and 1.36-1-13 
(A) were derived by limiting dilution of the 1.36 line. Serological  test: protein A assay. 
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FIGURE 8.  Expression of FD antigen by SK-MEL- 131 melanoma cells: comparison of direct 
protein A assays and quantitative absorption analysis. Lines 2.42 (column I), 3.44 (column 2), 
3.45  (column  3),  and  1.36  were derived  from parental  SK-MEL-131  cells and  individual 
sublines (columns 4-15) were derived from the 1.36 line (see Fig. 7). (*) No absorption of FD 
reactivity with a 30 ~1 cell pellet. 
FD serum  with  SK-MEL-131  cell  lines or sublines  expressing  low or high  levels 
of FD antigen. 
Biochemical Characterization of the FD Antigen.  FD serum immunoprecipitated 
a  90,000  dalton  component  from  ~25I-labeled  membrane  preparations  of SK- 
MEL-131  cells (Fig.  9).  This component  showed  an  isoelectric  point  (pI) of 5.5 
in  two-dimensional  gel  electrophoresis.  The  90,000  dalton  component  was not 
immunoprecipitated  from lysates of SK-MEL-131  cells metabolically labeled with 
[SSS]methionine  or  [SH]glucosamine,  but  it  was  detected  with  [3H]mannose- 
labeled  samples  (Fig.  9).  Similar  to  the  restricted  reactivity  of FD  sera  for SK- 
MEL-131  cells  in direct  tests  and  absorption  tests (see above),  the  immunopre- 
cipitating  activity of FD serum  for labeled  membrane  preparations  of SK-MEL- 
131  cells could be absorbed only by SK-MEL-131  cells, but not by any of the  14 1228  CLASS  1 (UNIQUE) GLYCOPROTEIN OF  HUMAN MELANOMA 
FIGURE 9.  Immunoprecipitates of 12~I-labeled  SK-MEL-131 cell membrane preparations 
(1-5) or [SH]mannose-labeled  SK-MEL-131  cell lysates (6-7) with normal  human  serum (1, 6), 
FD serum (March 1981) (2, 7), or FD serum absorbed with SK-MEL-131 cells (3), allogeneic 
melanoma SK-MEL-28  (4), or allogeneic  bladder carcinoma 253-J (5). A component of 90,000 
dahons is precipitated from 125I- or [SH]mannose-labeled  SK-MEL-131 by FD serum. The 
reactivity of FD serum is specifically  absorbed by SK-MEL-131 cells, but not by the two 
allogeneic tumor cell lines. 
other  cell  lines  tested,  including  four  melanomas,  three  astrocytomas,  four 
carcinomas,  two  cultures  of normal  fibroblasts,  or  by  autologous  EBV-trans- 
formed lymphocytes (Fig.  9).  Further evidence indicating that the cell surface 
reactivity and immunoprecipitating activity of FD serum are directed against the 
same determinant(s) came from cotyping a  series of 15  serum specimens from 
patient FD for both activities and finding a direct correspondence between titers 
in serological reactions and immunoprecipitating activity. 
A 90,000 dalton component was also immunoprecipitated from spent medium 
obtained from SK-MEL-131  cultures grown in serum-free medium, which had 
been  labeled  with  ~25I after  uhracentrifugation and  10-fold  concentration  by 
pressure dialysis. This antigen preparation was fractionated on 14 different lectin 
columns (see  Materials and  Methods),  and the  effluent and  eluate  from  each 
column were  tested  by immunoprecipitation.  The  90,000  dalton antigen  was 
found in the effluent in each case, and, with the exception of the Con A column, 
no antigen was detected in the eluate. With the Con A column, about one-third 
of the  recovered  antigen was  in  the  eluate  fraction.  When  a  l~SI-labeled  SK- 
MEL-131  cell  membrane  preparation  was  similarly  fractionated  on  a  Con  A 
column,  the  antigen  was  not  present  in  the  effluent but  was  detected  in  the 
eluate, indicating a  difference between the antigen present in the medium and 
the antigen present in the membrane. 
Discussion 
The description of the  FD Class  1 melanoma antigen brings the number of 
such antigens that have been serologically defined in melanoma to six. Whether 
they belong to a  single family of related molecules or represent  products that 
are  structurally unrelated  remains  to  be  determined.  As previous attempts  to 
characterize Class  1 tumor antigens by immunoprecipitation were unsuccessful, REAL ET AL.  1229 
the fact that FD antigen could be precipitated by autologous sera and identified 
as a  90,000  dalton  glycoprotein is an  important step  in  the analysis of these 
antigens.  The  generation  of mouse  monoclonal  antibodies  to  the  different 
epitopes on the 90,000 dalton glycoprotein may provide insight into some of the 
key questions  about  Class  1  tumor  antigens:  Are  there  structurally  related 
products on all  tumors? Do normal cells express such molecules? What  is the 
relation of Class  1 tumor antigens to other polymorphic systems, such as major 
histocompatibility complex antigens and Ig products? 
A class of tumor antigens known from work with chemically induced tumors 
of inbred rodents shows the same restriction to individual tumors as the Class  1 
tumor antigens of humans. These individually specific antigens of mouse and rat 
tumors  were  initially  detected  by  transplantation  techniques  involving  graft 
rejection in  preimmunized animals (19).  Although much effort has gone into 
developing serological reagents to define these antigens, this has generally not 
been successful. However, studies with one tumor (BALB Meth A) have resulted 
in the production of a  mouse antibody to a restricted antigen that parallels the 
distribution of the transplantation antigen on this tumor (20) and that is coded 
for by genes associated with the IgH region of chromosome 12 (21). Biochemical 
characterization of the Meth A  transplantation antigen has been facilitated by 
the finding that the cytosol is a rich source of the Meth A antigen (22) and recent 
evidence indicates that molecules of approximately 75,000-86,000  daltons are 
responsible for transplantation rejection (23-25).  Another example of an indi- 
vidually distinct transplantation antigen that has been serologically defined was 
recently reported by Srivastava and Das in studies of a  chemically induced rat 
hepatoma (26).  This antigen was found to have a  molecular mass of 95,000- 
100,000  daltons.  Whether the  individually distinct  antigens  of experimental 
tumors and the Class 1 antigens of human tumors are related also remains to be 
determined. 
Antibodies to  Class  1 antigens  have been  identified with  low frequency in 
patients with melanoma (1).  Although this could indicate that such antigens are 
present on only a small proportion of melanomas, there are a number of other 
reasons why antibody is found so infrequently, including poor immunogenicity 
of Class  1 antigens, loss of antigen expression after in  vitro culture, and the 
possibility that recognition of Class  1 antigens is primarily in  the province of 
cellular immunity and not humoral immunity. Another fact that may contribute 
to the low frequency of detection of Class 1 reactivity relates to heterogeneity in 
the levels of antigen expressed by cultured tumor cells. This was emphasized in 
the study of the DX Class  1 melanoma antigen (6).  Cell lines were established 
from six  metastatic deposits occurring in patient DX.  Only one of these lines 
expressed sufficient antigen to permit detection of autologous antibody, even 
though four of the five other DX lines expressed the same antigen at lower levels 
(as shown in absorption tests). The analysis of the AU Class 1 melanoma antigen 
illustrated another problem  with  regard to  target  cells in  the study of these 
antigens: an unpredictable cyclic variation in the expression of AU antigen (2). 
AU melanoma cells that showed strong expression of AU antigen on one day 
(titer 1:128-1:512) became nonreactive the next day and then strongly reactive 
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in AU antigen expression were analyzed, including culture conditions, cell cycle, 
and  passage generation,  but no explanation  emerged  from these studies.  The 
present  analysis  of the  FD antigen  also reveals a  marked  variation  in  antigen 
expression by FD melanoma cells, but, in this case, antigen loss was clearly related 
to time of in  vitro culture.  Early cultures of FD melanoma had strong Class  1 
antigen  expression,  whereas  later  cultures  showed  progressive  diminution  in 
antigenic expression. Limiting dilution experiments with early FD cultures were 
carried out to determine whether subsequent antigen loss affected the population 
as a  whole or was due to the emergence of low expression variants.  Sublines of 
FD melanoma have been isolated that have maintained  stable expression of FD 
antigen over a period of up to 26 mo, favoring the idea that the loss of antigen 
expression by FD cultures represents the outgrowth of low expression variants. 
To deal with this problem of antigen variability of melanoma cells in the search 
for Class  1 antigens,  we are  now deriving  a  panel  of cloned  lines  from  each 
melanoma specimen as the source of target cells for initial serological tests, rather 
than depending on a single culture from each specimen, as we have in the past. 
The  failure  to  immunoprecipitate  seroiogically  defined  Class  1  melanoma 
antigens in previous work may have several explanations,  including  insufficient 
antibody  levels,  antibodies  that  do  not  immunoprecipitate  effectively,  poor 
radiolabeling of Class 1 tumor antigens, or the relative paucity of such molecules 
on melanoma cells. Although  FD antigen could be labeled by 1251 and by [SH]- 
mannose,  it  could  not  be  immunoprecipitated  from  cells  labeled  with  [3H]- 
glucosamine or [~SS]methionine, and this could be due to a peculiar carbohydrate 
or amino acid composition or to a slow rate of synthesis, among other explana- 
tions. The latter possibility is suggested by the slow rate of reappearance of FD 
antigen  after trypsinization  of target cells. The  finding of FD antigen  in spent 
medium provides an additional source of antigen for purification and character- 
ization.  The antigen  in spent medium differs from the membrane-bound  form 
in binding less strongly to Con A. Whether FD is a true secreted protein or its 
presence in the culture medium is due to passive shedding from the cell mem- 
brane needs to be determined. Further biochemical and genetic characterization 
of the FD antigen and additional examples of similarly defined Class 1 melanoma 
antigens  will  be necessary before the significance of these antigens  in terms of 
immune  responses to tumors and  relation  to malignant  transformation  can  be 
assessed. 
Summary 
Analysis  of the  humoral  immune  response  of patients  with  melanoma  has 
identified a small group of individuals with antibody to cell surface antigens that 
are restricted to autologous melanoma cells. These antigens, referred to as Class 
1 or unique tumor antigens, are demonstrated by reactions between serum and 
cultured melanoma cells from the same patient and absorption tests with autolo- 
gous and allogeneic normal and malignant cells to determine antibody specificity. 
Five Class  1 melanoma antigens have been defined to date, but insight into the 
nature  of these antigens  has been limited because antibodies  identifying these 
antigens  lacked detectable immunoprecipitating  activity. We have now defined 
a  Class  1  melanoma  antigen  (designated  FD)  that  is  immunoprecipitated  by REAL ET  AL.  1231 
autologous antibody. FD antigen is identified by an IgG antibody present in the 
sera  of patient  FD,  and  peak  titers  of  this  antibody  in  tests  with  cultured 
autologous melanoma cells are in the range of 1:2048.  By absorption tests, FD 
antigen could not be  detected on any other cell  type,  including 33  allogeneic 
melanomas.  Prolonged  culture  of  FD  melanoma  cells  resulted  in  decreased 
expression  of FD antigen,  but sublines  could be  obtained  with stable  antigen 
expression. FD antigen is trypsin and heat sensitive, neuraminidase resistant, and 
is  shed in  the  culture medium.  Immunoprecipitation of 125I-labeled cell  mem- 
brane  preparations  revealed  a  90,000  dalton  component  of pI  5.5.  Serum 
immunoprecipitating activity could be absorbed by autologous melanoma cells 
but not by autologous B cells or allogeneic cell lines. A  component of the same 
molecular mass could be precipitated from lysates of cells metabolically labeled 
with  [3H]mannose.  The  membrane  form of the  FD  antigen binds strongly to 
Con A-Sepharose  and can be eluted with methyl-o~-n-mannoside. The identifi- 
cation of a precipitating Class  1 antigenic system of melanoma facilitates efforts 
to generate monoclonal antibodies to this tumor antigen and to clone its coding 
sequence. 
We are  grateful to  Dr.  Philip Livingston for valuable contributions to the study, Dr. 
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Bettina Fliegel for excellent technical assistance. 
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